참고문헌
- Addison CL, Bramson JL, Hitt MM, et al (1998). Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther, 5, 1400-9. https://doi.org/10.1038/sj.gt.3300731
- Alemany R (2007). Cancer selective adenoviruses. Mol Aspects Med, 28, 42-58. https://doi.org/10.1016/j.mam.2006.12.002
- Anderson RD, Haskell RE, Xia H, et al (2000). A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther, 7, 1034-8. https://doi.org/10.1038/sj.gt.3301197
- Bellew S, Del Rosso JQ, Kim GK (2009). Skin cancer in asians: part 2: melanoma. J Clin Aesthet Dermatol, 2, 34-6.
- Bischoff JR, Kirn DH, Williams A, et al (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274, 373-6. https://doi.org/10.1126/science.274.5286.373
- Debatin KM (1997). Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst, 89, 750-1. https://doi.org/10.1093/jnci/89.11.750
- Douglas JT (2007). Adenoviral vectors for gene therapy. Mol Biotechnol, 36, 71-80. https://doi.org/10.1007/s12033-007-0021-5
- El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
- Ghosh SS, Gopinath P, Ramesh A (2006). Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol, 133, 9-29. https://doi.org/10.1385/ABAB:133:1:9
- Gross A, McDonnell JM, Korsmeyer SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev, 13, 1899-911. https://doi.org/10.1101/gad.13.15.1899
- Hall MA, Cleveland JL (2007). Clearing the TRAIL for Cancer Therapy. Cancer Cell, 12, 4-6. https://doi.org/10.1016/j.ccr.2007.06.011
- Harlin H, Reffey SB, Duckett CS, et al (2001). Characterization of XIAP-deficient mice. Mol Cell Biol, 21, 3604-8. https://doi.org/10.1128/MCB.21.10.3604-3608.2001
- Haviv YS (2009). A simplified in vitro ligation approach to clone an E1B55k-deleted double-targeted conditionally-replicative adenovirus. Virol J, 6, 18. https://doi.org/10.1186/1743-422X-6-18
- Heise C, Sampson-Johannes A, Williams A, et al (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med, 3, 639-45. https://doi.org/10.1038/nm0697-639
- Hermiston TW, Kuhn I (2002). Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther, 9, 1022-35. https://doi.org/10.1038/sj.cgt.7700542
- Holcik M, Korneluk RG (2001). XIAP, the guardian angel. Nat Rev Mol Cell Biol, 2, 550-6. https://doi.org/10.1038/35080103
- Holcik M, Yeh C, Korneluk RG, et al (2000). Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene, 19, 4174-7. https://doi.org/10.1038/sj.onc.1203765
- Holoch PA, Griffith TS (2009). TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol, 625, 63-72. https://doi.org/10.1016/j.ejphar.2009.06.066
- Huang X, Lin T, Gu J, et al (2002). Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther, 9, 1379-86. https://doi.org/10.1038/sj.gt.3301810
- Huang Y, Sheikh MS (2007). TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol, 224, 284-9. https://doi.org/10.1016/j.taap.2006.12.007
- Huerta-Yepez S, Vega M, Jazirehi A, et al (2004). Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene, 23, 4993-5003. https://doi.org/10.1038/sj.onc.1207655
- Hunter AM, LaCasse EC, Korneluk RG (2007). The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis, 12, 1543-68. https://doi.org/10.1007/s10495-007-0087-3
- Jiang H, Conrad C, Fueyo J, et al (2003). Oncolytic adenoviruses for malignant glioma therapy. Front Biosci, 8, d577-88. https://doi.org/10.2741/923
- Kaufmann SH and Earnshaw WC (2000). Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 256, 42-49. https://doi.org/10.1006/excr.2000.4838
- Khuri FR, Nemunaitis J, Ganly I, et al (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6, 879-885. https://doi.org/10.1038/78638
- Kirn D, Martuza RL, Zwiebel J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med, 7, 781-7. https://doi.org/10.1038/89901
- Mahalingam D, Oldenhuis CN, Szegezdi E, et al (2011). Targeting trail towards the clinic. Curr Drug Targets, 12, 2079-90. https://doi.org/10.2174/138945011798829357
- McManus DC, Lefebvre CA, Cherton-Horvat G, et al (2004). Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene, 23, 8105-17. https://doi.org/10.1038/sj.onc.1207967
- Mitry RR, Mansour MR, Havlik R, et al (2000). Gene therapy for liver tumours. Adv Exp Med Biol, 465, 193-205.
- Opyrchal M, Aderca I, Galanis E (2009). Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol, 542, 705-17. https://doi.org/10.1007/978-1-59745-561-9_35
- Rosato RR, Dai Y, Almenara JA, et al (2004). Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia, 18, 1780-8. https://doi.org/10.1038/sj.leu.2403491
- Ruiz J, Qian C, Drozdzik M, et al (1999). Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat, 6, 17-34. https://doi.org/10.1046/j.1365-2893.1999.6120136.x
- Sharma A, Tandon M, Bangari DS, et al (2009). Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther, 4, 117-38. https://doi.org/10.2174/157488509788185123
- Shi RX, Ong CN, Shen HM (2005). Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res, 65, 7815-23.
- Short JJ, Curiel DT (2009). Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther, 8, 2096-102. https://doi.org/10.1158/1535-7163.MCT-09-0367
- Suliman A, Lam A, Datta R, et al (2001). Intracellular mechanisms of TRAIL: apoptosis through mitochondrialdependent and -independent pathways. Oncogene, 20, 2122-33. https://doi.org/10.1038/sj.onc.1204282
- Verma IM, Somia N (1997). Gene therapy-promises, problems and prospects. Nature, 389, 239-42. https://doi.org/10.1038/38410
- Volpers C, Kochanek S (2004). Adenoviral vectors for gene transfer and therapy. J Gene Med, 6, S164-71. https://doi.org/10.1097/00125817-200405000-00013
- von Haefen C, Gillissen B, Hemmati PG, et al (2004). Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene, 23, 8320-32. https://doi.org/10.1038/sj.onc.1207971
- Walczak H, Krammer PH (2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res, 256, 58-66. https://doi.org/10.1006/excr.2000.4840
- Walczak H, Miller RE, Ariail K, et al (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63. https://doi.org/10.1038/5517
- Wang S (2010). TRAIL: a sword for killing tumors. Curr Med Chem, 17, 3309-17. https://doi.org/10.2174/092986710793176285
- Wang S, El-Deiry WS (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene, 22, 8628-33. https://doi.org/10.1038/sj.onc.1207232
- Zhang S, Shen HM and Ong CN (2005). Down-regulation of c-FLIP contributes to the sensitization effect of 3, 3'-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther, 4, 1972-81. https://doi.org/10.1158/1535-7163.MCT-05-0249
- Zhao L, Dong A, Gu J, et al (2006). The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther, 13, 1011-22. https://doi.org/10.1038/sj.cgt.7700969
- Zhu ZB, Lu B, Park M, et al (2008). Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol, 32, 1179-88.
피인용 문헌
- Effect of Embelin on TRAIL Receptor 2 mAb-induced Apoptosis of TRAIL-resistant A549 Non-small Cell Lung Cancer Cells vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.6115
- XIAP Associated Factor 1 (XAF1) Represses Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and Regulates Invasion, Cell Cycle, Apoptosis, and Cisplatin Sensitivity of Ovarian Carcinoma Cells vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2453